How to Get Tresiba in Delaware: Prescriptions, Telehealth, and Pharmacy Access

What Is Tresiba and Why Do Delaware Patients Request It

Tresiba is a once-daily basal insulin with a half-life of approximately 25 hours and an action duration exceeding 42 hours, making it the longest-acting basal insulin currently on the U.S. market. [1] Its flat, peakless pharmacokinetic profile reduces glycemic variability compared to older basal insulins, a property confirmed in multiple phase 3 trials. [2]

The FDA approved insulin degludec (Tresiba) in September 2015 for adults with type 1 and type 2 diabetes, and subsequently extended approval to pediatric patients aged 1 year and older in 2017. [3] The label specifies subcutaneous administration once daily at any time of day, which gives patients scheduling flexibility that glargine U-100 products do not formally permit. [3]

Delaware has approximately 87,000 adults living with diagnosed diabetes, representing roughly 11.5% of the adult population according to CDC Behavioral Risk Factor Surveillance System data. [4] A meaningful share of those patients are candidates for basal insulin therapy, and Tresiba is frequently requested by patients who have experienced nocturnal hypoglycemia or glycemic instability on glargine or detemir.

The DEVOTE trial (N=7,637) compared insulin degludec U-200 to insulin glargine U-100 over 2 years in high-cardiovascular-risk patients with type 2 diabetes. Degludec produced a 53% lower rate of severe hypoglycemia (1.48 vs. 3.28 episodes per patient-year, P<0.001) and was non-inferior for major adverse cardiovascular events. [5] That hypoglycemia advantage is one of the primary clinical reasons Delaware providers and patients choose Tresiba over older basal insulins.

The Novo Nordisk prescribing information notes a mean A1c reduction of approximately 1.1 to 1.6 percentage points in phase 3 studies, comparable to glargine, but with consistently fewer hypoglycemic episodes. [3]

How to Get a Tresiba Prescription in Delaware

Any licensed Delaware prescriber, including MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs), can write a Tresiba prescription. Delaware grants full independent prescribing authority to advanced-practice nurses under Title 24, Chapter 19 of the Delaware Code, so an NP working in a telehealth setting can prescribe insulin degludec without physician countersignature. [6]

The simplest path to a prescription follows four steps. First, schedule an appointment with a Delaware-licensed provider. Second, share recent lab results (A1c, fasting glucose, renal function, and a prior insulin history if applicable). Third, the provider writes the prescription electronically. Fourth, you or the provider sends it to a Delaware pharmacy or a mail-order pharmacy licensed to ship into Delaware.

A key clinical decision the prescriber makes is whether to start Tresiba as a unit-for-unit switch from a previous basal insulin or at a reduced dose. The FDA label recommends starting at 80% of the previous basal insulin dose when converting from any other basal insulin, then titrating upward based on fasting glucose targets. [3] Most providers target a fasting glucose of 80 to 130 mg/dL per the American Diabetes Association Standards of Care. [7]

The HealthRX clinical team uses a three-tier decision tree for Delaware patients requesting Tresiba: (1) if the patient has a prior basal insulin and A1c above 8.0%, convert unit-for-unit; (2) if the patient has a prior basal insulin and recurrent hypoglycemia, convert at 80% and titrate over 4 weeks; (3) if the patient is insulin-naive, start at 10 units once daily and titrate by 2 units every 3 days as tolerated, consistent with the ADA dosing guidance. [7]

Telehealth Prescribing for Tresiba in Delaware

Delaware permits telehealth prescribing of prescription medications, including Schedule II-V controlled substances with appropriate protocols, and insulin is a non-controlled prescription drug that faces no additional telehealth restrictions. [8] A provider licensed in Delaware may initiate a Tresiba prescription via synchronous video visit after establishing a valid patient-provider relationship, which Delaware defines as a clinical encounter sufficient to support prescribing.

Telehealth platforms that hold Delaware prescribing authority commonly require a 30 to 45-minute initial visit covering diabetes history, current medications, recent labs, hypoglycemia episodes, and injection technique. Follow-up visits are typically 15 to 20 minutes.

The ADA 2024 Standards of Care state: "Telehealth may be used to initiate and adjust insulin therapy when the provider can adequately assess the patient's clinical status and review objective glucose data." [7] Delaware law aligns with that guidance without adding state-specific barriers.

A practical advantage for Delaware patients using telehealth is prescription routing. The telehealth provider can transmit the e-prescription directly to a local Delaware pharmacy or to a NABP-accredited mail-order pharmacy, avoiding an extra step. Retail pharmacies in Wilmington, Dover, and Newark fill Tresiba from manufacturer stock and can typically provide same-day or next-day pickup on a new prescription when inventory permits.

For patients enrolled in Delaware Medicaid (Diamond State Health Plan), the telehealth visit itself is reimbursable when conducted via synchronous audio-video, per Delaware Health and Social Services telemedicine policy. [8]

What Labs Are Needed Before Starting Tresiba in Delaware

Labs are not legally required before a provider writes a Tresiba prescription, but they are clinically standard and almost universally requested. Expect your Delaware provider to want the following results, ideally within the past 3 months. [7]

Hemoglobin A1c tells the provider your average glucose over the prior 10 to 12 weeks and anchors the starting dose decision. A basic metabolic panel, particularly creatinine and eGFR, informs dosing safety because severe renal impairment (eGFR <15 mL/min/1.73m2) requires closer monitoring, though no dose adjustment is mandated in the Tresiba label. [3] Fasting plasma glucose gives a real-time anchor. For patients with suspected type 1 diabetes, a C-peptide level and GAD65 antibody test may be ordered to confirm insulin deficiency. [9]

If you are applying for prior authorization through Delaware Medicaid or a commercial insurer, a documented A1c above a specified threshold (commonly 7.5% to 9.0% depending on the plan) and evidence of prior insulin failure or intolerance are typically required. [10] Pull together any pharmacy records showing previous insulin fills, as these are the most efficient proof of prior insulin trial.

Continuous glucose monitoring (CGM) data, if available, can substitute for or supplement point-in-time glucose values and is increasingly accepted by Delaware insurance reviewers as objective evidence of glycemic instability. [9]

Delaware Medicaid Prior Authorization for Tresiba

Delaware Medicaid (Diamond State Health Plan, managed through Centene/Highmark affiliates) covers insulin degludec for both type 1 and type 2 diabetes with prior authorization. [10] Without PA, the out-of-pocket retail cost of Tresiba runs approximately $330 to $380 per 5-pen box (3 mL per pen, 100 units/mL), depending on the pharmacy.

Standard PA requirements across Delaware Medicaid and most commercial plans in the state include: a current A1c result, documentation of at least one prior basal insulin trial (typically glargine or detemir) with recorded failure or intolerance, a prescriber attestation letter explaining the clinical rationale for degludec, and an ICD-10 diagnosis code of E10 (type 1) or E11 (type 2). [10]

The ADA Standards of Care are direct on this point: "Insulin is a life-sustaining medication and prior authorization processes that delay access contribute to preventable harm." [7] Delaware providers frequently reference this language in PA appeal letters when initial requests are denied.

Processing time for a PA decision is typically 3 to 5 business days for standard review and 24 to 72 hours for urgent review when the prescriber documents clinical urgency. If denied, Delaware law provides a formal appeals process including an independent external review within 45 days. [10]

For patients who need Tresiba immediately while awaiting PA approval, the Novo Nordisk Patient Assistance Program provides free medication to uninsured or underinsured patients with household incomes up to 400% of the federal poverty level. [11] The Novo Nordisk savings card (NovoCare) also caps out-of-pocket cost at $99 per 90-day supply for commercially insured patients who do not use government insurance. [11]

503A Compounding Pharmacies and Insulin Degludec in Delaware

Delaware-licensed 503A pharmacies are permitted to compound insulin degludec for individual patients when a valid prescription is presented and a documented medical need exists. [12] The FDA distinguishes between 503A pharmacies (patient-specific compounding) and 503B outsourcing facilities (large-scale, facility-registered compounding). Delaware has multiple 503A pharmacies with compounding capability; they operate under state Board of Pharmacy oversight.

Compounded insulin degludec is not bioequivalent to commercially manufactured Tresiba in the regulatory sense, and the FDA has not evaluated compounded versions for safety or efficacy. [12] Clinically, compounding is most relevant for patients requiring non-standard concentrations (for example, a pediatric patient needing very small doses, where the standard U-100 pen delivers doses in 1-unit increments that may exceed the required precision). [3]

Most Delaware patients obtain brand Tresiba through commercial channels rather than compounding. Compounded degludec is a secondary option when brand availability is disrupted or when concentration customization is medically necessary, as supported by the FDA's drug shortage and compounding guidance. [12]

Transferring a Tresiba Prescription to Delaware

If you are relocating to Delaware or spending an extended period in the state, transferring a Tresiba prescription is straightforward. Delaware pharmacies can accept electronic transfers of non-controlled prescriptions from out-of-state pharmacies. Insulin degludec is not a controlled substance, so there are no DEA or state controlled-substance transfer restrictions. [13]

The receiving Delaware pharmacy contacts the originating pharmacy directly, verifies the prescription details (prescriber NPI, quantity, refills remaining), and enters the transfer into its dispensing system. Depending on insurance, you may need your Delaware insurer to authorize the fill at the new pharmacy. A prior-authorization approval issued in another state does not automatically transfer to Delaware Medicaid or a Delaware-based commercial plan. [10]

If you are using a national mail-order pharmacy (CVS Caremark, Express Scripts, OptumRx), no transfer is necessary because those pharmacies ship to Delaware addresses from their existing prescription records.

For patients who held a Tresiba prescription from an out-of-state telehealth provider, the prescriber must hold a Delaware license or an interstate telemedicine compact authorization to write new fills. Delaware joined the Interstate Medical Licensure Compact (IMLC), allowing multistate-licensed physicians to prescribe across state lines. [13] NPs are covered under the Nurse Licensure Compact (NLC), to which Delaware also belongs.

Dosing, Titration, and Storage for Delaware Patients

The Tresiba prescribing information specifies once-daily dosing at any time of day, with at least 8 hours between consecutive doses. [3] Starting doses in insulin-naive adults with type 2 diabetes are typically 10 units per day, titrated by 2 units every 3 days to achieve fasting glucose targets. For type 1 diabetes, the label recommends basal insulin comprise approximately 30 to 50% of total daily insulin dose, with the remainder covered by rapid-acting insulin at meals. [3]

The SWITCH 1 and SWITCH 2 crossover trials are particularly instructive for Delaware clinicians managing titration. SWITCH 2 (N=721, type 2 diabetes) showed that insulin degludec produced a statistically significant 30% lower rate of overall symptomatic hypoglycemia compared to insulin glargine U-100 during the maintenance phase (rate ratio 0.70 to 95% CI 0.61-0.80, P<0.001). [14] SWITCH 1 (N=501, type 1 diabetes) showed a 35% lower rate of nocturnal symptomatic hypoglycemia versus glargine U-100 (P<0.001). [15]

Storage instructions matter for Delaware patients ordering by mail in summer months. Unopened Tresiba pens may be stored in the refrigerator at 36 to 46 degrees Fahrenheit until the expiration date. Once in use, a Tresiba pen may be stored at room temperature below 86 degrees Fahrenheit for up to 56 days, the longest in-use storage period of any commercially available basal insulin. [3] The 56-day window (double the 28-day limit of glargine products) reduces insulin waste for patients who use small daily doses.

Cardiovascular Safety and Renal Considerations

The DEVOTE cardiovascular outcomes trial enrolled 7,637 patients with type 2 diabetes and high cardiovascular risk, following them for a median of 2.0 years. [5] Insulin degludec was non-inferior to insulin glargine U-100 for major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke), with a hazard ratio of 0.91 (95% CI 0.78-1.06). [5] This trial provided the FDA with the cardiovascular safety data required for basal insulins under the 2008 FDA guidance on cardiovascular risk in diabetes drugs. [3]

Renal impairment does not require dose adjustment per the Tresiba label, but the prescribing information states that patients with renal impairment may require more frequent glucose monitoring. [3] The same applies to hepatic impairment. Delaware patients on hemodialysis or with eGFR <30 mL/min/1.73m2 should discuss monitoring frequency with their nephrologist and endocrinologist jointly. [9]

Drug interactions relevant to Delaware prescribers include: concurrent use of thiazolidinediones (pioglitazone) may cause fluid retention and require dose reduction; beta-blockers may mask hypoglycemia symptoms; and GLP-1 receptor agonists (semaglutide, liraglutide) may reduce basal insulin requirements by 15 to 30%, necessitating titration. [3] The ADA 2024 Standards of Care specifically recommend considering basal insulin dose reduction when initiating a GLP-1 receptor agonist. [7]

Finding a Delaware Provider or Telehealth Service for Tresiba

Delaware has 3 endocrinology practices in Wilmington, 2 in Newark, and 1 in Dover that regularly manage basal insulin initiation, according to Delaware Health Care Commission provider directories. [16] Wait times for new endocrinology appointments in Delaware average 6 to 12 weeks at most practices, which has increased demand for telehealth alternatives.

A telehealth provider must hold a Delaware medical license or qualify under the IMLC or NLC compact to prescribe to Delaware patients. [13] Before booking, confirm that the platform's prescribers hold Delaware licensure. Most national telehealth platforms (including HealthRX) verify this during patient enrollment.

The average telehealth visit for insulin initiation or management runs $75 to $150 out of pocket when not covered by insurance. Delaware's Medicaid telehealth reimbursement policy covers synchronous audio-video visits with qualified providers at parity with in-person visits for covered services including diabetes management. [8]

Once the prescription is written, typical fulfillment time is 1 to 2 business days at a retail Delaware pharmacy or 3 to 7 business days through a mail-order pharmacy. Urgent fills, such as when a patient is out of insulin, can sometimes be managed with a 30-day emergency supply at retail under Delaware pharmacy board emergency dispensing rules. [16]